✦ LIBER ✦

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome

✍ Scribed by Raj K. Patel; Nicholas C. Lea; Michael A. Heneghan; Nigel B. Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D. Heaton; Ghulam J. Mufti

Book ID: 119759243
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 173 KB
Volume: 130
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2006.04.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

218 JAK2 V617F mutation in extrahepatic

218 JAK2 V617F mutation in extrahepatic portal vein obstruction and budd-chiari syndrome

✍ E.M. Fabris; R. Reati; A. Dell'Era; P. Bucciarelli; G. Bergamaschi; G. Barosi; M 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Prevalence of the JAK2V617F mutation in

Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: A prospective study

✍ Xingshun Qi; Cheng Zhang; Guohong Han; Wei Zhang; Chuangye He; Zhanxin Yin; Zhiw 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB

P124 The prevalence of JAK2 V617F mutati

P124 The prevalence of JAK2 V617F mutation in myelodysplastic syndrome

✍ M. Radič Antolic; R. Zadro; P. Rončevič; S. Bašič Kinda; B. Labar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB

reductase enzyme mutation, 5Gdel1G of gen PAI-1) and hyperhomocysteinaemia up to 24 mcmol/L were also discovered. Patient received interferon-alpha, hydroxyurea, acetylsalicylic acid, sulodexide, vitamin therapy B6, B12 with positive effect. We observed disappearance of ascites, reduction of the siz

Meta-analysis: the significance of scree

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd–Chiari syndrome and portal venous system thrombosis

✍ X. Qi; Z. Yang; M. Bai; X. Shi; G. Han; D. Fan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

JAK2 (V617F) mutation levels in patients

JAK2 (V617F) mutation levels in patients affected by Budd-Chiari syndrome and non-cirrhotic extra-hepatic portal vein obstruction

✍ C. Marzano; A. Rago; S. Angeloni; A. Fama; C. Laganà; A. Tafuri; O. Riggio 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

The JAK2 V617F activating tyrosine kinas

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

✍ Steensma, David P. (author);Dewald, Gordon W. (author);Lasho, Terra L. (author); 📂 Article 📅 2005 🏛 American Society of Hematology 🌐 English ⚖ 116 KB